Gilead Sciences, Inc. (NASDAQ: GILD) has announced that its Chief Medical Officer, Merdad Parsey, MD, PhD, will be leaving the company in early 2025. Until then, Dr. Parsey will continue in his role and support the transition to a new CMO. During his tenure, the company's portfolio has more than doubled, and there are currently 54 ongoing clinical trials across virology, oncology, and inflammation.
Under Dr. Parsey's leadership, Gilead has made significant progress in its global clinical development and medical affairs organizations. The company has advanced market-leading treatments in virology, established an oncology pipeline, and developed therapeutics.
Dr. Parsey expressed his excitement about the work done to build a strong and diverse clinical pipeline with the potential to deliver on the commitment to improve global health.
Gilead Sciences, Inc. is a biopharmaceutical company committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. The company operates in more than 35 countries worldwide, with headquarters in Foster City, California.
The press release did not include specific financial metrics or comparisons between periods, and no forward-looking financial guidance was provided. Today the company's shares have moved 1.9% to a price of $72.97. If you want to know more, read the company's complete 8-K report here.
